This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

75/100

✓ Peer-reviewed alzhub usefulness score 75 out of 100. Treatments

Topic: Drug trials: efficacy and safety

There were 132 846 individuals (mean [SD] age, 80.4 [7.6] years; 61.8% women; mean [SD] body mass index [BMI], 25.5 [4.6]) with a diagnosis of dementia included in cohort 1, 159 419 individuals (mean [SD] age, 81.2 [7.6] years; 59.7% women; mean [SD] body mass index [BMI], 25.6 [4.7]) with a diagnosis of dementia included in cohort 2, and 92 328 individuals with a diagnosis of dementia included in cohort 3 (mean [SD] age, 80.9 [7.7] years; 58.5% women; mean [SD] body mass index [BMI], 25.5 [4.7]). The adjusted hazard ratio (HR) for donepezil compared with rivastigmine or galantamine (cohort 1) was 0.95 (95% CI, 0.67-1.35). The adjusted HR for memantine compared with donepezil, rivastigmine, or galantamine (cohort 2) was 1.03 (95% CI, 0.83-1.27). The adjusted HR for memantine vs rivastigmine or galantamine only (cohort 3) was 1.24 (95% CI, 0.83-1.86). CONCLUSIONS AND RELEVANCE: This cohort study of patients with dementia found no significant associations between memantine or donepezil compared with other dementia medications and the risk of development of AMD. Further research is recommended to examine any possible pathophysiological protective action of memantine and other dementia medications against the development of AMD.

Key findings

There were 132 846 individuals (mean [SD] age, 80.4 [7.6] years; 61.8% women; mean [SD] body mass index [BMI], 25.5 [4.6]) with a diagnosis of dementia included in cohort 1, 159 419 individuals (mean [SD] age, 81.2 [7.6] years; 59.7% women; mean [SD] body mass index [BMI], 25.6 [4.7]) with a diagnosis of dementia included in cohort 2, and 92 328 individuals with a diagnosis of dementia included in cohort 3 (mean [SD] age, 80.9 [7.7] years; 58.5% women; mean [SD] body mass index [BMI], 25.5 [4.7]).
The adjusted hazard ratio (HR) for donepezil compared with rivastigmine or galantamine (cohort 1) was 0.95 (95% CI, 0.67-1.35).
The adjusted HR for memantine compared with donepezil, rivastigmine, or galantamine (cohort 2) was 1.03 (95% CI, 0.83-1.27).
The adjusted HR for memantine vs rivastigmine or galantamine only (cohort 3) was 1.24 (95% CI, 0.83-1.86).
CONCLUSIONS AND RELEVANCE: This cohort study of patients with dementia found no significant associations between memantine or donepezil compared with other dementia medications and the risk of development of AMD.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Study designcohort study
Participants846
Effect size61.8%; 59.7%; 58.5%
Evidence strengthModerate

How this study scored 75/100

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 42 of the 56 points we could judge it on, which is 75 out of 100.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (JAMA network open)
Journal's citation record	— / 4	No journal record from OpenAlex — left out of this score
Study design	7 / 12	A cohort study following people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2024 — within 3 year(s) of the newest study here
Sample size	2 / 4	846 participants
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	— / 7	No citation count (not found in OpenAlex) — left out of this score
Citations per year	— / 5	No citation count or no year — left out of this score
Impact for its field and year	— / 6	No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here	— / 6	Not yet checked against this library's citation graph — left out of this score
Still being cited	— / 4	No yearly citation counts — left out of this score
Senior author's track record	— / 4	Senior author's record not available — left out of this score
Institution's track record	— / 3	No institution listed in OpenAlex — left out of this score
Multi-centre collaboration	— / 3	Institutions not listed — left out of this score
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 39446320)
Free to read	— / 2	Access not recorded — left out of this score
Points	42 / 56	Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 42 of the 56 points we could judge it on is 75 out of 100.
Total	75 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

APA 7th

Wang, J., Antza, C., Lee, W. H., Coker, J., Keane, P. A., Denniston, A. K., et al. (2024). Pharmacologic Treatments for Dementia and the Risk of Developing Age-Related Macular Degeneration. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2024.41166

Vancouver

Wang J, Antza C, Lee WH, Coker J, Keane PA, Denniston AK, et al. Pharmacologic Treatments for Dementia and the Risk of Developing Age-Related Macular Degeneration. JAMA network open. 2024. doi:10.1001/jamanetworkopen.2024.41166. PMID: 39446320.

BibTeX

@article{wang2024-39446320,
  author  = {Wang, Jingya and Antza, Christina and Lee, Wen Hwa and Coker, Jesse and Keane, Pearse A and Denniston, Alastair K and Nirantharakumar, Krishnarajah and Adderley, Nicola J},
  title   = {{Pharmacologic Treatments for Dementia and the Risk of Developing Age-Related Macular Degeneration}},
  journal = {JAMA network open},
  year    = {2024},
  doi     = {10.1001/jamanetworkopen.2024.41166},
  pmid    = {39446320},
  url     = {https://doi.org/10.1001/jamanetworkopen.2024.41166}
}

Related studies in Treatments

Also tagged “cholinesterase”

271 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 271 tagged studies.

Similar studies

More on Treatments

See all studies in Treatments →